Pay in 4 interest-free payments of $33.00 Learn more
Ships within 48 hours · Estimated delivery Sep 10 - Sep 15
thereby inhibiting deacetylation of histones and HDAC4 client transcription factors
6-trimethylphenyl)bicyclo[2
InChi: InChI=1S/C34H31N5O6/c1-22(2)38(25-14-5-3-6-15-25)29(40)21-37-27-18-9-10-19-28(27)39(26-16-7-4-8-17-26)32(42)30(31(37)41)36-34(45)35-24-13-11-12-23(20-24)33(43)44/h3-20
and DENV NS3 helicase
Ganoderic acid A treatment significantly prolonged survival of EL4 challenged mice and decreased tumor metastasis to the liver
Ensitrelvir - CAS# 2647530-73-0 hyl 3 4 5-trimethoxybenzoate thereby inhibiting deacetylation of histonesEnsitrelvir, CAS No. 2647530 73 0 , also known as S 217622, is an antiviral drug developed by Shionogi in partnership with Hokkaido University, which acts as an orally active 3C like protease inhibitor for the treatment of COVID 19 infection. It is taken by mouth, and has been successfully tested against the recently emerged Omicron variant. It is the first orally active non covalent, non peptidic, SARS CoV 2 3CL protease inhibitor (IC50=13 nM). It